ArticleHaematologica2025
The pivotal role of von Willebrand factor binding to platelet αIIbβ3 in stabilizing the formation of a platelet plug at sites of injury.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The interaction between von Willebrand factor (VWF) and platelet αIIbβ3 is thought to be essential for clot formation at injury sites, but its biological properties remain poorly understood due to the complexity and overlap with other αIIbβ3 ligands. Here, we developed a novel binding assay using a recombinant αIIbβ3 headpiece to evaluate VWF-αIIbβ3 binding in plasma from 441 Zimmerman Program participants. The VWF:αIIbβ3 to VWF:Ag ratio was significantly lower in patients with type-1, 2A, and 2B VWD than healthy controls. We identified five index cases with the p.R2464C variant in the VWF-C-domain, where affected family members displayed significantly reduced VWF:αIIbβ3/VWF:Ag ratios. To investigate the function of the VWF-αIIbβ3 interaction, we created a mouse model (VWFRGES/RGES) by altering the VWF-RGDS motif to RGES, which abolished VWF-αIIbβ3 binding. VWFRGES/RGES mice exhibited increased blood loss following lateral tail vein transection and reduced thrombus stability in a laser injury model, showing a 59-fold larger AUC for emboli compared to wild-type. However, initial bleeding times and outcomes of carotid artery injury were comparable. Overall, our VWF:αIIbβ3 binding assay is valuable for characterizing VWD, and the VWFRGES mouse model underscores the physiological significance of the VWF-αIIbβ3 interaction, highlighting that VWF-αIIbβ3 interaction is crucial for stabilizing platelet plug formation at injury sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.